Tenaya Therapeutics Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the biotech company's gene therapy pipeline

Mar. 14, 2026 at 8:43am

Got story updates? Submit your updates here. ›

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have received an average 'Moderate Buy' rating from seven brokerages covering the stock, according to MarketBeat Ratings. One analyst has a 'sell' recommendation, five have 'buy' ratings, and one has a 'strong buy' on the biotech company, which is focused on developing gene therapy solutions for cardiovascular diseases.

Why it matters

Tenaya Therapeutics is a clinical-stage biotech company working on innovative gene therapies to treat genetic cardiomyopathies and other inherited heart disorders. The 'Moderate Buy' rating from analysts suggests they see promise in the company's pipeline and approach, which could be significant for patients suffering from these rare and often fatal conditions.

The details

The average 12-month price target for Tenaya Therapeutics stock is $4.00 among the analysts covering the company. In recent research reports, analysts have cited the company's proprietary adeno-associated virus (AAV) platform and its potential to deliver durable, one-time treatments as reasons for their positive outlook. However, one analyst has a 'sell' rating, citing concerns over the company's progress and valuation.

  • Tenaya Therapeutics was founded in 2018 and is headquartered in San Carlos, California.
  • The company reported its latest quarterly earnings results on March 11, 2026.

The players

Tenaya Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing gene therapy solutions for cardiovascular diseases.

HC Wainwright

A research firm that lowered its price target on Tenaya Therapeutics from $5.00 to $3.00 and maintained a 'buy' rating.

Weiss Ratings

A research firm that assigned a 'sell (d-)' rating on Tenaya Therapeutics' shares.

Morgan Stanley

A research firm that set a $2.00 price target on Tenaya Therapeutics' stock.

Wall Street Zen

A research firm that downgraded Tenaya Therapeutics from a 'hold' rating to a 'sell' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Tenaya Therapeutics' 'Moderate Buy' rating from analysts suggests its gene therapy pipeline for cardiovascular diseases holds promise, though the company faces some skepticism from certain research firms. As a clinical-stage biotech, Tenaya's progress will be closely watched by investors and the medical community as it works to advance its innovative treatments.